This Entry
PermalinkURI
URI Label
Revisions
Add to List
Edit Entry
Export:
XML
Archives
- November 2017 (1)
- July 2017 (1)
- February 2017 (1)
- January 2017 (2)
- May 2016 (1)
- April 2016 (1)
- December 2015 (1)
- November 2015 (2)
- August 2015 (1)
- June 2015 (1)
- May 2015 (3)
- April 2015 (1)
- January 2015 (1)
- December 2014 (1)
- November 2014 (2)
- August 2014 (4)
- July 2014 (2)
- June 2014 (3)
- May 2014 (1)
- April 2014 (3)
- March 2014 (2)
- February 2014 (2)
- January 2014 (1)
- December 2013 (2)
- November 2013 (3)
- September 2013 (1)
- August 2013 (1)
- July 2013 (2)
- June 2013 (2)
- April 2013 (1)
- March 2013 (1)
- February 2013 (2)
- January 2013 (1)
- December 2012 (2)
- November 2012 (1)
- September 2012 (2)
- June 2012 (2)
- April 2012 (4)
- March 2012 (2)
- March 2012 (2)
- January 2012 (3)
Authors
Sections
- 3D7 IC50 Avery Lab (3)
- AstraZeneca (2)
- MetID (3)
- Potencies GSK (1)
- Potencies Guy (1)
- Syngene (8)
- UCSD (1)
- Biology (37)
- DMPK (2)
- Dundee (4)
- GSH-EE - Chapman Lab (2)
- GSK PRR Assay (1)
- Imperial DGFA (1)
- Kirk Lab (5)
- Metabolism (1)
Tools
Show/Hide QR CodeShow/Hide Keys
Thirteen Series 4 compounds have been submitted for biological evauation against plasmodium falciparum and TB (awaiting details of TB assay). The compounds are a mixture of ether, thioether, amine and amide linked compounds, along with two key building blocks.
Single Shot Potencies were obtained: Single Shot Potencies for Compounds Submitted to GSK
Additionally, some Series 3 compounds were sent for testing.
Some compounds inherited from at TB project also being performed in the Todd Lab were also sent for evaluation.
Data to be posted later.
Originally authored by Alice
Linked Posts
Attached Files
Series 3 Compounds.cdxml
Series 4 Compounds.cdxml
TB Inherited Compounds.cdxml
Series 3 Compounds.png
Series 4 Compounds.png
TB Inherited Compounds.png